Analisi sito web takeda.com
Takeda Pharmaceuticals: Global Homepage
Generato il Marzo 04 2026 10:15 AM
Statistiche non aggiornate? AGGIORNA !
Il punteggio e 53/100
SEO Content
Title
Takeda Pharmaceuticals: Global Homepage
Lunghezza : 39
Perfetto, il tuo title contiene tra 10 e 70 caratteri.
Description
Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.
Lunghezza : 131
Grande, la tua meta description contiene tra 70 e 160 caratteri.
Keywords
Molto male. Non abbiamo trovato meta keywords nella tua pagina. Usa questo generatore gratuito online di meta tags per creare keywords.
Og Meta Properties
Buono, questa pagina sfrutta i vantaggi Og Properties.
| Proprieta | Contenuto |
|---|---|
| title | Takeda Pharmaceuticals: Global Homepage |
| description | Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future. |
| url | https://www.takeda.com/ |
| locale | en |
| image | http://assets-dam.takeda.com/image/upload/v1683892920/Global/OG%20Logo.jpg |
| image:secure_url | https://assets-dam.takeda.com/image/upload/v1683892920/Global/OG%20Logo.jpg |
| image:width | 1200 |
| image:height | 627 |
| image:type | image |
| image:alt | Takeda Pharmaceuticals: Global Homepage |
| type | website |
Headings
| H1 | H2 | H3 | H4 | H5 | H6 |
| 1 | 5 | 14 | 0 | 0 | 0 |
- [H1] Takeda Pharmaceuticals: Global Homepage
- [H2] Expanding access to hereditary angioedema care in Vietnam
- [H2] Recent News
- [H2] Better Health, Brighter Future
- [H2] Our Areas of Focus
- [H2] Sign up for investors newsletter
- [H3] Takeda - Global
- [H3] Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
- [H3] Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
- [H3] U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
- [H3] Takeda Reports Third-Quarter FY2025 Results – Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind – Progressing Toward Three Transformative Launches Ahead
- [H3] Join Us
- [H3] Investors
- [H3] R&D
- [H3] Gastrointestinal and Inflammation
- [H3] Rare Diseases
- [H3] Plasma-Derived Therapies
- [H3] Oncology
- [H3] Neuroscience
- [H3] Vaccines
Images
Abbiamo trovato 6 immagini in questa pagina web.
Buono, molte o tutte le tue immagini hanno attributo alt
Text/HTML Ratio
Ratio : 2%
Il rapporto testo/codice HTML di questa pagina e inferiore a 15 percento, questo significa che il tuo sito web necessita probabilmente di molto piu contenuto.
Flash
Perfetto, non e stato rilevato contenuto Flash in questa pagina.
Iframe
Grande, non sono stati rilevati Iframes in questa pagina.
SEO Links
URL Rewrite
Buono. I tuoi links appaiono friendly!
Underscores in the URLs
Perfetto! Non sono stati rilevati underscores nei tuoi URLs.
In-page links
Abbiamo trovato un totale di 134 links inclusi 0 link(s) a files
| Anchor | Type | Juice |
|---|---|---|
| Our Company | Interno | Passing Juice |
| Leadership | Interno | Passing Juice |
| Sustainability Approach | Interno | Passing Juice |
| Access to Medicines | Interno | Passing Juice |
| Sustainability Disclosures | Interno | Passing Juice |
| Ethics | Interno | Passing Juice |
| Transparency Disclosures | Interno | Passing Juice |
| Positions | Interno | Passing Juice |
| Corporate Giving | Interno | Passing Juice |
| Governance Strategy | Interno | Passing Juice |
| Governance Structure | Interno | Passing Juice |
| Charters and Reports | Interno | Passing Juice |
| Areas of Focus | Interno | Passing Juice |
| Research and Development | Interno | Passing Juice |
| Pipeline | Interno | Passing Juice |
| Our Products | Interno | Passing Juice |
| Manufacturing | Interno | Passing Juice |
| Suppliers | Interno | Passing Juice |
| Clinical Trials | Interno | Passing Juice |
| Our Stories | Interno | Passing Juice |
| Press Releases | Interno | Passing Juice |
| Statements | Interno | Passing Juice |
| Media Resources | Interno | Passing Juice |
| Overview | Interno | Passing Juice |
| Financial Results | Interno | Passing Juice |
| Investor Events | Interno | Passing Juice |
| Investor Contact | Interno | Passing Juice |
| Careers | Interno | Passing Juice |
| Leadership | Interno | Passing Juice |
| Sustainability Approach | Interno | Passing Juice |
| Access to Medicines | Interno | Passing Juice |
| Ethics | Interno | Passing Juice |
| Corporate Giving | Interno | Passing Juice |
| Governance Structure | Interno | Passing Juice |
| Charters and Reports | Interno | Passing Juice |
| Research and Development | Interno | Passing Juice |
| Pipeline | Interno | Passing Juice |
| Our Products | Interno | Passing Juice |
| Manufacturing | Interno | Passing Juice |
| Suppliers | Interno | Passing Juice |
| Clinical Trials | Interno | Passing Juice |
| Press Releases | Interno | Passing Juice |
| Statements | Interno | Passing Juice |
| Media Resources | Interno | Passing Juice |
| Overview | Interno | Passing Juice |
| Financial Results | Interno | Passing Juice |
| Investor Events | Interno | Passing Juice |
| Investor Contact | Interno | Passing Juice |
| English | Interno | Passing Juice |
| Japanese | Interno | Passing Juice |
| English | Interno | Passing Juice |
| French | Interno | Passing Juice |
| Arabic | Interno | Passing Juice |
| Spanish | Interno | Passing Juice |
| English | Interno | Passing Juice |
| German | Interno | Passing Juice |
| Russian | Interno | Passing Juice |
| English | Interno | Passing Juice |
| French | Interno | Passing Juice |
| Dutch | Interno | Passing Juice |
| Bosnian | Interno | Passing Juice |
| Portuguese | Interno | Passing Juice |
| Bulgarian | Interno | Passing Juice |
| English | Interno | Passing Juice |
| French | Interno | Passing Juice |
| Spanish | Interno | Passing Juice |
| Chinese | Interno | Passing Juice |
| Spanish | Interno | Passing Juice |
| Croatian | Interno | Passing Juice |
| Czech | Interno | Passing Juice |
| Danish | Interno | Passing Juice |
| Spanish | Interno | Passing Juice |
| English | Interno | Passing Juice |
| Arabic | Interno | Passing Juice |
| Estonian | Interno | Passing Juice |
| Finnish | Interno | Passing Juice |
| French | Interno | Passing Juice |
| German | Interno | Passing Juice |
| Greek | Interno | Passing Juice |
| English | Interno | Passing Juice |
| Chinese | Interno | Passing Juice |
| Hungarian | Interno | Passing Juice |
| English | Interno | Passing Juice |
| Indonesian | Interno | Passing Juice |
| English | Interno | Passing Juice |
| Hebrew | Interno | Passing Juice |
| Italian | Interno | Passing Juice |
| Kazakh | Interno | Passing Juice |
| Russian | Interno | Passing Juice |
| Korean | Interno | Passing Juice |
| Latvian | Interno | Passing Juice |
| Lithuanian | Interno | Passing Juice |
| English | Interno | Passing Juice |
| Spanish | Interno | Passing Juice |
| Dutch | Interno | Passing Juice |
| English | Interno | Passing Juice |
| Norweigan | Interno | Passing Juice |
| Spanish | Interno | Passing Juice |
| English | Interno | Passing Juice |
| Polish | Interno | Passing Juice |
| Portuguese | Interno | Passing Juice |
| Romanian | Interno | Passing Juice |
| Russian | Interno | Passing Juice |
| English | Interno | Passing Juice |
| Arabic | Interno | Passing Juice |
| Serbian | Interno | Passing Juice |
| English | Interno | Passing Juice |
| Slovak | Interno | Passing Juice |
| Slovenian | Interno | Passing Juice |
| English | Interno | Passing Juice |
| Spanish | Interno | Passing Juice |
| Swedish | Interno | Passing Juice |
| German | Interno | Passing Juice |
| French | Interno | Passing Juice |
| Chinese | Interno | Passing Juice |
| Thai | Interno | Passing Juice |
| Turkish | Interno | Passing Juice |
| Ukrainian | Interno | Passing Juice |
| English | Interno | Passing Juice |
| Arabic | Interno | Passing Juice |
| English | Interno | Passing Juice |
| English | Interno | Passing Juice |
| English | Interno | Passing Juice |
| - | Interno | Passing Juice |
| Locations | Interno | Passing Juice |
| Contact us | Interno | Passing Juice |
| Careers | Interno | Passing Juice |
| Financial Highlights | Interno | Passing Juice |
| HCPs | Interno | Passing Juice |
| Patients | Interno | Passing Juice |
| Terms and Conditions | Interno | Passing Juice |
| Privacy Notice | Interno | Passing Juice |
| Cookie Policy | Interno | Passing Juice |
| Accessibility Statement | Interno | Passing Juice |
SEO Keywords
Keywords Cloud
french diseases more takeda corporate patients spanish arabic english drug
Consistenza Keywords
| Keyword | Contenuto | Title | Keywords | Description | Headings |
|---|---|---|---|---|---|
| english | 38 |  |
|
|
|
| spanish | 14 | |
|
|
|
| diseases | 11 | |
|
|
 |
| french | 10 | |
|
|
|
| takeda | 9 | |
|
|
|
Usabilita
Url
Dominio : takeda.com
Lunghezza : 10
Favicon
Grande, il tuo sito usa una favicon.
Stampabilita
Non abbiamo riscontrato codice CSS Print-Friendly.
Lingua
Buono. La tua lingua dichiarata en.
Dublin Core
Questa pagina non sfrutta i vantaggi di Dublin Core.
Documento
Doctype
HTML 5
Encoding
Perfetto. Hai dichiarato che il tuo charset e UTF-8.
Validita W3C
Errori : 0
Avvisi : 0
Email Privacy
Attenzione! E stato trovato almeno un indirizzo mail in plain text. Usa antispam protector gratuito per nascondere gli indirizzi mail agli spammers.
Deprecated HTML
Grande! Non abbiamo trovato tags HTML deprecati nel tuo codice.
Suggerimenti per velocizzare
|
Eccellente, il tuo sito web non utilizza nested tables. |
|
Molto male, il tuo sito web utilizza stili CSS inline. |
|
Molto male, il tuo sito web ha troppi file CSS files (piu di 4). |
|
Molto male, il tuo sito web ha troppi file JS (piu di 6). |
|
Perfetto, il vostro sito si avvale di gzip. |
Mobile
Mobile Optimization
|
Apple Icon |
|
Meta Viewport Tag |
|
Flash content |
Ottimizzazione
XML Sitemap
Grande, il vostro sito ha una sitemap XML.
| https://www.takeda.com/sitemap.xml |
Robots.txt
https://takeda.com/robots.txt
Grande, il vostro sito ha un file robots.txt.
Analytics
Non trovato
Non abbiamo rilevato uno strumento di analisi installato su questo sito web.
Web analytics consentono di misurare l'attività dei visitatori sul tuo sito web. Si dovrebbe avere installato almeno un strumento di analisi, ma può anche essere buona per installare una seconda, al fine di un controllo incrociato dei dati.
PageSpeed Insights
Dispositivo
Categorie
Free SEO Testing Tool
Free SEO Testing Tool e uno strumento di ottimizzazione per i motori di ricerca (seo tool) che serve per analizzare le tue pagine web